MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on July 30, 2004; DOI: 10.1124/mol.104.002279


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.002279v1
66/6/1500    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Author home page(s):
xuechu zhen
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by zhen, x.
Right arrow Articles by Friedman, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by zhen, x.
Right arrow Articles by Friedman, E.


Received for publication May 4, 2004.
Revised July 28, 2004.
Accepted for publication July 29, 2004.

Regulation of cdk5 and CaMK II by PI-linked dopamine receptor in rat brain

xuechu zhen 1*, Satindra Goswami 1, Syed Amir Abdali 1, Mara Gil 1, Kalindi Bakshi 1, Eitan Friedman 1

1 CUNY Medical School

* Address correspondence to: E-mail: xuechu{at}med.cuny.edu

Abstract

A brain dopamine receptor that modulates phosphatidylinositol metabolism via the activation of PLC {beta} has been previously described. The present study aims to define the down stream signaling cascade initiated by the PI-linked dopamine receptor. Incubation of rat brain frontal cortical slices with SKF83959, a recently identified selective agonist of the PI-linked D1 -like dopamine receptor, elicited transient time-and dose-dependent stimulations of cdk5 and CaMKII activities. The stimulation of these kinases is blocked by 20 µM SCH23390 or the PLC{beta} antagonist, U-73122, and is attenuated by the protein kinase inhibitor, calphostin C or by the intracellular calcium chelator BAPTA, indicating, that SKF83959 stimulates cdk5 and CaMK II activities via a PI-linked D1-like dopamine receptor and PLC {beta}and is dependent on PKC and calcium. Although cdk5 and CaMK II is physically associated in native brain tissue, no change in this association was observed in response to SKF 83959 stimulation, or to the inhibition of either cdk5 by roscovitine or of CaMK, by KN93, suggesting that SKF83959-mediated stimulation of cdk5 or CaMK II is independent of the other kinase and that the association of the two kinases is not modulated by change of kinase activity. Moreover, we found that cdk5 phosphorylates DARPP-32 (Thr-75) while CaMK II is responsible for the activation of CREB in response to SKF83959 stimulation. The present data provides the first insight into the signaling mechanism for the PI-linked dopamine receptor. This information, in turn, may help in exploring the functional consequences of stimulation of this brain receptor.


Key words: Dopamine, Gq/11 family, Phospholipase C's, IP3/DAG, Protein Kinase C, Phosphorylation/Dephosphorylation, CREB, Synaptic plasticity


This article has been cited by other articles:


Home page
J. Neurophysiol.Home page
L. Chen, J. D. Bohanick, M. Nishihara, J. K. Seamans, and C. R. Yang
Dopamine D1/5 Receptor-Mediated Long-Term Potentiation of Intrinsic Excitability in Rat Prefrontal Cortical Neurons: Ca2+-Dependent Intracellular Signaling
J Neurophysiol, March 1, 2007; 97(3): 2448 - 2464.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. J. Rashid, C. H. So, M. M. C. Kong, T. Furtak, M. El-Ghundi, R. Cheng, B. F. O'Dowd, and S. R. George
D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum
PNAS, January 9, 2007; 104(2): 654 - 659.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics